Form 4: OptiNose Executive Michael F. Marino III Receives Stock Options and Restricted Stock Units

Michael F. Marino III, Chief Legal Officer & Corp Sec of OptiNose, Inc., reports the acquisition of stock options and restricted stock units.

Summary

• On February 28, 2024, Michael F. Marino III, Chief Legal Officer & Corp Sec of OptiNose, Inc., was granted 280,000 restricted stock units (RSUs) and options to purchase 140,000 shares of common stock.
• The RSUs vest over a four-year period, with 25% vesting on February 28, 2025, and the remainder vesting in equal quarterly installments over the subsequent three years, contingent upon continued service and potentially accelerated vesting based on the company's net revenue and operating profit performance.
• The stock options also vest over a four-year period, with 25% vesting on February 28, 2025, and the remainder vesting in equal monthly installments over the following three years, subject to continued service.
• The exercise price for the stock options is $1.815 per share.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects standard executive compensation practices, incentivizing performance and retention. There are no immediate negative implications.

Positives

• The grant of RSUs and stock options aligns the executive's interests with those of the shareholders.
• The vesting schedules incentivize continued service and performance.

Risks

• The vesting of the RSUs and stock options is contingent upon continued service, creating a potential risk if the executive leaves the company.
• The accelerated vesting of RSUs is dependent on the company achieving certain performance criteria, which may not be met.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the RSUs and stock options.

Industry Context

Executive compensation packages including stock options and RSUs are common in the pharmaceutical industry to attract and retain talent and align their interests with company performance.

Comparison to Industry Standards

• Stock option and RSU grants are a standard component of executive compensation packages in the pharmaceutical industry, often benchmarked against peer companies of similar size and stage of development.
• Vesting schedules are typically structured to incentivize long-term commitment and performance, with variations depending on company-specific goals and industry norms.
• Companies like Amgen, Regeneron, and Vertex Pharmaceuticals also utilize similar equity-based compensation strategies for their executives.

Stakeholder Impact

• The grant of equity-based compensation can positively impact shareholders by aligning executive interests with long-term company performance.
• Employees may view the executive compensation package as a sign of the company's commitment to its leadership team.

Key Dates